Clover Health (CLOV) executive receives 191,261 RSUs vesting through 2030
Clover Health Investments' CEO of Clover Care Services, Brady Patrick Priest, was granted 191,261 shares of Class A Common Stock as time-based restricted stock units (RSUs). These RSUs, part of his equity compensation with no cash purchase price, will vest over time, with 25% vesting on April 1, 2027, and the remainder in quarterly installments through April 1, 2030, contingent on his continued employment. Following this award, Priest directly holds 2,189,845 shares of Class A Common Stock.
Clover Health (CLOV) awards 382,522 RSUs to Chief Legal Officer
Clover Health Investments (CLOV) has granted its Chief Legal Officer, Karen Soares, 382,522 Restricted Stock Units (RSUs) of Class A common stock. These RSUs were awarded at no cash cost, increasing her direct ownership to 1,582,583 shares. The vesting schedule dictates that 25% will vest on April 1, 2027, with the remainder vesting in quarterly installments until April 1, 2030, contingent on her continued employment.
Clover Health (CLOV) executive granted 267,766 RSUs and reports large share holdings
Clover Health executive Wai Conrad (CEO of Counterpart Health) was granted 267,766 Restricted Stock Units (RSUs) of Class A common stock, valued at $0.00 per share, indicating a compensation grant. These RSUs will vest over time, with 25% vesting on April 1, 2027, and the remainder in quarterly installments until April 1, 2030, conditional on his continued service. Following this transaction, Mr. Conrad directly holds 1,193,377 shares, and a family trust holds an additional 1,610,482 shares indirectly.
Clover Health (CLOV) grants 159,384 RSU-based shares to Medicare Advantage CEO
Clover Health has granted Jamie L. Reynoso, CEO of Medicare Advantage, 159,384 shares of Class A common stock in the form of time-based restricted stock units (RSUs) as equity compensation. These RSUs were awarded at no cash cost per share and will vest over time, with 25% vesting on April 1, 2027, and the remainder in quarterly installments until April 1, 2030, subject to continued service. Following this award, Reynoso's direct holdings in Class A common stock total 2,876,119 shares.
Clover Health Announces CFO Transition and Reaffirms 2026 Outlook
Clover Health announced a planned CFO transition, with Peter Kuipers stepping down and interim roles assigned to Clay Thornton and Joseph Oldakowski. The company reaffirmed its full-year 2026 financial guidance, emphasizing confidence in its strategy and financial trajectory despite the leadership change. Spark's AI Analyst rates CLOV stock as Neutral due to mixed financial quality and technical pressures, acknowledging the positive aspects of membership growth and profitability ambitions.
Vanguard amends Schedule 13G/A; reports 0 shares in Clover Health (CLOV)
The Vanguard Group has filed an amended Schedule 13G/A, reporting zero beneficial ownership in Clover Health Investments Corp (CLOV). This change results from an internal realignment within Vanguard on January 12, 2026, which led certain subsidiaries to report their beneficial ownership separately in reliance on SEC Release No. 34-39538. The filing, signed on March 26, 2026, indicates that Vanguard no longer holds reportable beneficial ownership in Clover Health under this amendment.
Clover Health CEO Reynoso sells $11,141 in shares By Investing.com
Clover Health Investments Corp.'s CEO of Medicare Advantage, Jamie L. Reynoso, sold 5,833 shares of Class A Common Stock for approximately $11,141. The transaction occurred on March 18, 2026, under a pre-arranged trading plan, leaving Reynoso with over 2.7 million shares. This news follows Clover Health's recent Q4 2025 earnings report, which exceeded revenue expectations, and its announcement of becoming the first health insurance payer to operate on a CMS Aligned Network and TEFCA.
Clover Health (CLOV) Medicare Advantage CEO sells 5,833 shares in planned trade
Clover Health Investments' CEO of Medicare Advantage, Jamie L. Reynoso, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. This sale was executed on March 18, 2026, as part of a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. Following this transaction, Reynoso directly holds 2,716,735 Class A shares.
Clover Health (CLOV) exec Reynoso has shares withheld to cover RSU tax obligations
Clover Health Investments executive Jamie L. Reynoso had shares automatically withheld on March 14 and 15, 2026, to cover tax obligations arising from vested restricted stock units (RSUs). A total of 15,132 Class A Common shares were withheld at $1.98 per share, which were tax-withholding dispositions rather than open-market sales. Following these transactions, Reynoso directly holds 2,722,568 Class A shares.
Clover Health (CLOV) CEO has shares withheld to cover RSU taxes
Clover Health Investments, Corp.'s CEO of Counterpart Health, Conrad Wai, had 100,195 shares of Class A Common Stock automatically withheld on March 14, 2026, to cover tax obligations. This action was due to the vesting of the final portion of his time-based Restricted Stock Units (RSUs) granted in 2022. Following this, Wai directly holds 925,611 shares, with an additional 1,610,482 shares held indirectly in a family trust.
RSU vesting triggers tax share withholding at Clover Health (CLOV)
Clover Health Investments' General Counsel, Karen Soares, had 4,528 shares of Class A common stock withheld to cover tax obligations. This occurred on March 15, 2026, when 6.25% of her September 15, 2022, time-based RSU grant vested. After the withholding, Soares directly held 1,200,061 shares of Class A common stock.
Clover Health (CLOV) shares Q4 2025 supplemental shareholder Q&A in new 8-K
Clover Health Investments, Corp. (CLOV) has filed an 8-K announcing the publication of a supplemental shareholder Q&A for its fourth-quarter 2025 earnings. This Q&A, dated March 6, 2026, provides written responses to frequently asked questions from shareholders to enhance engagement. The document is furnished as Exhibit 99.1 and is also available on the company's investor relations website.
Clover Health (CLOV) Home Care CEO sells 175,000 shares
Brady Patrick Priest, CEO of Home Care at Clover Health Investments, sold 175,000 shares of Class A Common Stock on March 4, 2026. The shares were sold on the open market at a weighted average price of $2.17 per share, in multiple transactions ranging from $2.16 to $2.18. Following this sale, Priest directly owns 1,998,584 shares of Clover Health's Class A Common Stock.
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
Clover Health has become the first payer to go live on a CMS Aligned Network and TEFCA, facilitating real-time patient access to clinical and claims data in standardized FHIR formats. This achievement, made possible by a collaboration with Kno2 and Clover's subsidiary Counterpart Health, demonstrates that nationwide interoperable data exchange is achievable today. It allows patients to securely request health information and aims to enhance coordinated care within a value-based model.
175,000-share sale reported for Clover (NASDAQ: CLOV) on Form 144
A Form 144 filing for Clover Health Investments, Corp. (NASDAQ: CLOV) reported a proposed sale of 175,000 common shares. The filing, dated March 4, 2026, lists Morgan Stanley Smith Barney LLC as the broker-dealer and details restricted stock lots with various grant dates in 2025 and 2026. This type of filing is a notice of an intended sale rather than a confirmation of a completed transaction.
Clover Health Investments, Corp. (NASDAQ:CLOV) Receives Average Rating of "Hold" from Brokerages
Clover Health Investments, Corp. (NASDAQ:CLOV) has an average "Hold" rating from five brokerages, with a consensus 12-month price target of $3.23. Despite positive guidance for FY-2026 revenue ($2.8B–$2.9B) and projected GAAP profitability, Q4 EPS missed estimates, and the company remains unprofitable. Institutional investors hold 19.77% of the stock.
Medicare insurer Clover Health chases first full-year profit in 2026
Clover Health reported its full-year 2025 results, showing $1.924 billion in total revenues and Medicare Advantage membership of 113,803. The company also provided 2026 guidance, projecting its first full year of GAAP net income profitability between $0 million and $20 million on total revenues of $2.81 billion to $2.92 billion. Management attributed the expected profitability to improving cohort economics, Clover Assistant-driven care, and membership scaling, despite a GAAP net loss of $85.5 million in 2025.
CLOVER HEALTH INVESTMENTS, CORP. /DE SEC 10-K Report
Clover Health Investments, Corp. has released its annual Form 10-K report, detailing financial performance, business operations, and strategic initiatives. The company reported a significant increase in total revenues but also higher net losses and loss per share. Clover Health continues to focus on its Clover Assistant platform, geographical expansion, and new product launches like Counterpart Health, while navigating challenges in profitability, operational and regulatory risks, and market competition.
Clover Health (CLOV) targets 2026 GAAP profitability after 40% revenue growth
Clover Health reported strong 40% revenue growth in 2025, reaching $1.9 billion, and increased Medicare Advantage membership by 38% to 113,803. Despite a GAAP net loss of $86 million in 2025, the company achieved non-GAAP profitability with $22 million in Adjusted EBITDA and $20 million in Adjusted Net Income. Clover Health projects its first full year of GAAP net income profitability in 2026, with revenue guidance between $2.81 billion and $2.92 billion and Adjusted EBITDA of $50-$70 million.
Clover Health Investments, Corp. to Release Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health Investments, Corp. (CLOV) announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, 2026, followed by a webcast at 5:00 p.m. ET. The company, which focuses on providing healthcare to Medicare recipients through its software platform Clover Assistant, will discuss its financial performance and business updates. Investors can register for the webcast through the Investor Relations section of Clover Health's website.
Clover Health Investments, Corp. to Release Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Clover Health Investments, Corp. (CLOV) announced it will release its fourth quarter and full year 2025 financial results after market close on February 26, 2026. Management will host a webcast at 5:00 p.m. ET to discuss the results and business updates. The company is focused on providing healthcare access to Medicare recipients, leveraging its Clover Assistant software platform to improve clinical decision-making and health outcomes.
Clover Health CEO Reynoso sells $11860 in shares By Investing.com
Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, sold 4,597 shares for $11,860 on January 20, 2026, and an additional 14,732 shares for $41,396 on January 15, 2026, to cover tax obligations. Despite the company not being profitable in the last year, InvestingPro projects profitability in the current year, and analysts view the stock as slightly undervalued with price targets between $3.00 and $3.70. Clover Health also reported a significant increase in Medicare Advantage membership and aims for its first full-year GAAP Net Income profitability in 2026, though it missed Q3 2025 EPS estimates while exceeding revenue expectations.
Clover Health CEO Reynoso sells $11860 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 4,597 shares of Class A Common Stock for $11,860 on January 20, 2026, and an additional 14,732 shares for $41,396 on January 15, 2026, to cover tax obligations. Despite not being profitable in the past year, InvestingPro analysis anticipates Clover Health will achieve profitability this year, with a projected GAAP Net Income profitability in 2026. The company also reported a 53% year-over-year increase in Medicare Advantage membership and its stock is considered slightly undervalued by InvestingPro.
Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November
U.S. stocks traded lower on Wednesday, with the Nasdaq falling significantly, despite energy shares gaining and U.S. retail sales increasing by 0.6% in November. Several companies saw substantial stock movements: High Roller Technologies surged 289% following a new partnership, Clover Health Investments rose 10% on membership growth, and Inspire Veterinary Partners gained 78%. Conversely, BriaCell Therapeutics and Plus Therapeutics dropped over 30% after pricing public offerings, while Hub Cyber Security fell 39% following a reverse stock split.
Clover Health Reports 53% Medicare Advantage Membership Growth and Aims for First Full Year GAAP Net Income Profitability in 2026
Clover Health announced a significant 53% year-over-year increase in its Medicare Advantage membership for 2026, reaching approximately 153,000 members. This growth, driven by strategic market approaches and strong retention, positions the company for its first full year of GAAP Net Income profitability in 2026. Clover's PPO plan, which covers over 97% of its members, leads nationally in clinical quality, supported by its Clover Assistant technology to enhance patient outcomes.
Clover Health announces 53% growth in Medicare Advantage membership during AEP, increasing to 153,000 members as of January 1, 2026; expects first-ever full year GAAP net income profitability in 2026
Clover Health announced a significant 53% growth in its Medicare Advantage membership during the Annual Enrollment Period, reaching 153,000 members as of January 1, 2026. The company also anticipates achieving its first-ever full year GAAP net income profitability in 2026. This positive development signals strong company performance and a promising financial outlook for Clover Health.
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Rating of "Hold" by Analysts
Five analysts have given Clover Health Investments, Corp. (NASDAQ:CLOV) a consensus "Hold" rating, with an average 1-year price target of $3.23. The company recently reported a loss of ($0.05) EPS against an expected $0.02, while revenue beat expectations at $496.65 million. Clover Health remains unprofitable, with negative return on equity and net margin, and shares are trading around $2.60.
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Recommendation of "Hold" by Analysts
Clover Health Investments, Corp. (NASDAQ:CLOV) has received a consensus "Hold" recommendation from analysts, with an average 12-month price target of $3.23. The company recently missed EPS expectations but exceeded revenue forecasts, while institutional investors have adjusted their positions in the stock. CLOV shares are currently trading around $2.64 with a market capitalization of $1.36 billion.
Rhumbline Advisers Increases Position in Clover Health Investments, Corp. $CLOV
Rhumbline Advisers significantly increased its stake in Clover Health Investments (NASDAQ:CLOV) by 8,149.2% in the second quarter, now holding 584,459 shares valued at $1.63 million. Despite this increased institutional interest, analysts maintain a "Hold" consensus rating with a target price of $3.93, while the company faces challenges with missed EPS estimates and negative profitability metrics. Several other institutional investors also acquired new positions in CLOV during recent quarters, indicating varied sentiment towards the stock.
Soviero Asset Management LP Acquires 650,000 Shares of Clover Health Investments, Corp. $CLOV
Soviero Asset Management LP significantly increased its stake in Clover Health Investments, Corp. (NASDAQ:CLOV) by 260%, acquiring an additional 650,000 shares to total 900,000 shares worth approximately $2.51 million. Despite a recent EPS miss, the company reported revenue of $496.65 million, surpassing expectations. Analysts currently have a "Hold" consensus rating for CLOV, with an average price target of $3.93.
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Clover Health Investments, Corp. (NASDAQ:CLOV) has received a "Moderate Buy" consensus recommendation from six analysts, with an average 12-month price target of $3.93. The company recently reported a quarterly EPS of ($0.05), missing estimates, but revenue beat expectations at $496.65 million. Institutional investors have been increasing their stakes, and the stock currently trades around $2.28.
Clover Health's CFO Peter Kuipers to Present at 2025 Citi Global Healthcare Conference
Clover Health's CFO, Peter Kuipers, is scheduled to present at the 2025 Citi Global Healthcare Conference on December 4, 2025. The presentation will discuss the company's focus on improving healthcare access for Medicare beneficiaries through its Clover Assistant software platform. This engagement aims to increase investor visibility and highlight Clover Health's technological advancements and commitment to enhancing patient outcomes.
Clover Health Investments, Corp. (CLOV) Reports Break-Even Earnings for Q3
Clover Health Investments (CLOV) reported break-even quarterly earnings, surpassing the Zacks Consensus Estimate of a $0.02 loss per share for Q3 2025, and also exceeded revenue expectations with $496.65 million. The company has shown favorable estimate revisions recently, earning a Zacks Rank #2 (Buy), suggesting potential market outperformance. This positive outlook is supported by a 16.8% stock gain year-to-date, slightly outpacing the S&P 500.
Clover Health's CFO Peter Kuipers to Present at 2025 Citi Global Healthcare Conference
Clover Health's CFO, Peter Kuipers, is scheduled to present at the 2025 Citi Global Healthcare Conference on December 4, 2025, to discuss the company's commitment to improving healthcare access for Medicare patients through its Clover Assistant software platform. The company aims to enhance clinical decision-making, improve health outcomes, and reduce healthcare costs. The presentation will be webcast live on Clover Health's investor relations website, allowing investors to learn more about the company's technology and market potential.
Clover Health (Nasdaq: CLOV) posts 50% revenue growth to $497M in the third quarter
Clover Health reported Q3 2025 results showing a 50% year-over-year revenue increase to $496.7 million and a 35% rise in Medicare Advantage membership to 109,226. Despite a GAAP net loss of $24.4 million, the company achieved positive Adjusted EBITDA of $2.1 million for the quarter and $45 million year-to-date. Clover Health also raised its full-year 2025 guidance for average MA membership, insurance revenue, and Adjusted EBITDA, citing cohort economics and favorable CMS developments aimed at improving future profitability.
Clover Health Reports Third Quarter 2025 Results
Clover Health announced its Q3 2025 results, reporting a 35% year-over-year increase in Medicare Advantage membership and a 50% rise in total revenues to $497 million. The company achieved year-to-date positive Adjusted EBITDA profitability and raised its full-year 2025 guidance for membership, revenue, and profitability. Management anticipates achieving full-year GAAP Net Income in 2026, driven by strong cohort management, high retention, and favorable CMS rate updates.
CLOVER HEALTH INVESTMENTS, CORP. /DE SEC 10-K Report
Clover Health Investments, Corp. released its annual Form 10-K report, detailing an 8.8% increase in total revenues to $1,371.1 million and a significant reduction in net loss to $(43.0) million. The company reported substantial Medicare Advantage membership growth and improved CMS Star ratings, while also launching Counterpart Health to expand its technology's reach. The report outlines future outlooks, strategic initiatives, and challenges including profitability, operational risks, and a competitive landscape.
Clover Health Investments, Corp. Announces Step Down of Chelsea Clinton as from Board and Member of Talent and Compensation Committee and the Nominating and Corporate Governance Committee, Effective October 31, 2025
Clover Health Investments, Corp. announced that Chelsea Clinton will step down from its Board of Directors, effective October 31, 2025. Ms. Clinton, the longest-serving board member since early 2017, contributed significantly to the company's growth from a private entity to a publicly traded organization serving over 100,000 seniors. During her tenure, she served on the Talent & Compensation Committee and the Nominating and Corporate Governance Committee.
Clover Health Investments (NASDAQ:CLOV) Stock Price Up 8.7% - Here's What Happened
Clover Health Investments (NASDAQ:CLOV) saw its stock price increase by 8.7% during mid-day trading to $3.18. Analyst ratings resulted in an average "Hold" with a consensus price target of $4.03, despite some lowering price targets. Insider transactions show CEO Conrad Wai selling shares while Director Anna U. Loengard significantly increased her stake.
Clover Health Reaffirms Strong Growth Potential and Profitability Strategy Amid 2026 Star Ratings Announcement
Clover Health remains confident in achieving above-market membership growth and increasing Adjusted EBITDA profitability through 2027, despite its Medicare Advantage plans receiving 3.5 Stars for PPO and 4.0 Stars for HMO for the 2026 rating year. CEO Andrew Toy emphasizes that Clover's technology-driven approach, powered by Clover Assistant, enables it to deliver excellent healthcare outcomes and drive profitability independently of these Star ratings. The company continues to demonstrate strong clinical quality with high HEDIS scores and actively engages with CMS to advocate for a Star ratings methodology that better reflects actual health outcomes.
Clover Health Investments Corp (CLOV) Unveils Availity Essential for Administrative Tasks
Clover Health Investments Corp (CLOV) has launched Availity Essentials, a new portal designed to improve administrative efficiency for healthcare providers. This platform aims to streamline core tasks, reduce delays in patient care, and allow providers to focus more on patients. CEO Jamie Reynoso emphasized its role in easing administrative burdens and fostering better collaboration between health plans and providers.
Clover Health Investments, Corp. Partners with Availity to Enhance Provider Efficiency and Improve Patient Care
Clover Health Investments, Corp. has partnered with Availity to improve provider efficiency and patient access to care for Medicare beneficiaries. This multi-phase initiative aims to streamline administrative tasks like prior authorizations and eligibility checks through a new centralized portal, reducing burdens on healthcare providers. The collaboration underscores Clover Health's commitment to operational excellence, interoperability, and enhancing the patient experience by allowing providers to focus more on delivering quality care.
Loengard Anna U buys Clover Health investments (CLOV) shares By Investing.com
Anna U. Loengard, a director at Clover Health Investments Corp (NASDAQ:CLOV), purchased $68,755 worth of Class A Common Stock on August 13, 2025. This insider buying occurred as the stock saw an 18.5% surge in the past week and InvestingPro analysis suggests it is fairly valued. The purchases were made for custodial IRAs benefiting her children and align with broader management confidence, as indicated by active share buybacks and analyst targets ranging from $2.50 to $5.00.
Clover Health rises after former CEO buys shares
Clover Health's stock rose after its former CEO purchased shares. This often signals to investors that company insiders have confidence in its future prospects, potentially leading to increased market value.
Clover Health CEO Reynoso sells $19,718 in shares
Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, sold 6,823 shares of Class A Common Stock for $19,718 on August 4, 2025, under a Rule 10b5-1 trading plan. Despite the stock having declined 47.7% in six months, Clover Health recently reported Q2 2025 revenue of $477.62 million, surpassing analyst expectations. The company's management has also been actively buying back shares.
Clover Health Earnings Reveal Massive Growth: Revenue Jumps 34%, Medicare Membership Soars Past 106,000
Clover Health reported strong Q2 2025 results, with Medicare Advantage membership growing 32% year-over-year to 106,323 and total revenues increasing 34% to $478 million. Despite a GAAP net loss of $11 million, the company achieved Adjusted EBITDA and Adjusted Net income of $17 million each. Clover Health also updated its full-year 2025 guidance, increasing Medicare Advantage membership expectations and improving Adjusted SG&A projections, while attributing its success to its technology-first approach and the effectiveness of its AI-driven Clover Assistant in reducing hospitalizations and readmissions.
Why Is Clover Health (CLOV) Stock Soaring Today
Clover Health (CLOV) stock surged 9.5% today, driven by overall positive market sentiment ahead of a busy corporate earnings week. Despite previous volatility and a recent insider stock sale that caused a dip, the company's shares gained momentum as more than 85% of S&P 500 companies reporting earnings exceeded expectations. The rally occurred in the absence of any specific new catalysts for Clover Health.
Clover Health Investments, Corp. CFO Peter Kuipers to Present at Canaccord Genuity 45th Annual Growth Conference
Clover Health Investments, Corp. announced that CFO Peter Kuipers will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 11:00 a.m. ET. The company, which focuses on providing affordable, high-quality healthcare to seniors through its software platform, Clover Assistant, will make the presentation accessible via a live webcast on its investor relations website. This event is expected to highlight Clover Health's technology and its positive impact on patient outcomes and cost reduction.
Clover Health CEO Wai Conrad sells $49561 in shares
Clover Health CEO Wai Conrad sold 15,203 shares of Class A Common Stock for $49,561 on July 8, 2025, through a pre-arranged trading plan. Despite the sale, Conrad still directly holds 1,613,498 shares, and the company has shown strong financial health, with a 127% return over the past year. Clover Health also reported robust Q1 2025 results, including a 33% revenue increase and 30% Medicare Advantage membership growth, leading to raised full-year guidance.
Clover Health Investments, Corp. to Release Second Quarter 2025 Financial Results and Host Conference Call on August 5
Clover Health Investments, Corp. will release its Q2 2025 financial results after market close on August 5, 2025, followed by a conference call and webcast at 5:00 p.m. ET to discuss the company's performance. The company, which focuses on providing healthcare solutions for seniors using its Clover Assistant software, will make the webcast accessible via its Investor Relations website. This announcement comes amidst recent insider stock sales and varied institutional investor activity.
